Anti-CD14 Antibody Therapy for Ocular Fibrosis and Neovascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as wet AMD and pathological myopia, including anti-VEGF agents, are ineffective in inhibiting fibrosis, leading to significant vision loss despite inhibiting neovascularization, and there is a need for additional therapeutic options.
Innovation Solution
Targeting Cluster of Differentiation 14 (CD14) with anti-CD14 antagonist antibodies to reduce neovascularization and fibrosis in ocular diseases, providing a novel mechanism independent of anti-inflammatory and anti-angiogenic activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF agents are used to treat ocular diseases, then neovascularization is inhibited, but fibrosis is not inhibited leading to vision loss
Solution Approach 1:
The patent segments the therapeutic approach by introducing a second antibody (anti-CD14 or anti-MD2) that targets a different pathological mechanism (fibrosis) separately from the first antibody (anti-VEGF) that targets neovascularization. This segmentation allows each antibody to address its specific harmful factor independently, resolving the contradiction where anti-VEGF alone fails to inhibit fibrosis.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining two different antibodies with distinct mechanisms of action. The first antibody targets VEGF to inhibit neovascularization, while the second antibody targets CD14 or MD2 to inhibit fibrosis. This composite strategy addresses both harmful factors (neovascularization and fibrosis) simultaneously, resolving the limitation of single-antibody therapy.
2Duration of action of stationary object
If anti-VEGF therapy is continued long-term, then neovascularization progression is reduced, but vision loss still occurs due to fibrotic lesions and atrophy
Solution Approach 1:
The patent applies preliminary action by introducing the anti-fibrosis antibody (anti-CD14 or anti-MD2) alongside the anti-VEGF therapy from the outset, rather than waiting for fibrosis to develop. This preemptive approach prevents fibrotic lesion formation before they can cause vision loss, thereby improving vision retention throughout the long-term treatment duration.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining dual antibody therapy (anti-VEGF plus anti-CD14/anti-MD2) throughout the treatment period. This continuous dual-action approach simultaneously suppresses both neovascularization and fibrosis throughout the duration of treatment, preventing the development of fibrotic lesions and atrophy that would otherwise lead to vision loss over time.
Data Source
AI summary
This disclosure relates generally to methods and agents for treating an ocular disease or disorder. More particularly, the present disclosure relates to the use of CD14 antagonist antibodies for treating an ocular disease or disorder.